Understanding Real-world Perspectives of Healthcare Providers on Short-term Prevention for Migraine and Rimegepant Treatment Use by Patients: Findings from Cross-sectional Surveys
Teshamae Monteith1, Jessica Ailani2, Karina Nakajima3, Martine Maculaitis4, Elizabeth Brighton4, Nemin Chen4, Meghan Fajardo3, Feng Dai3, Karin Hygge Blakeman5, Lucy Abraham6, Jessica Cirillo3
1University of Miami, 2Medstar Health, 3Pfizer Inc., 4Oracle Life Sciences, 5Pfizer AB, 6Pfizer Ltd.
Objective:

To understand short-term prevention (STP) of migraine from the perspective of healthcare providers (HCPs) and rimegepant patient STP users.

Background:

STP is a time-limited treatment before migraine onset for patients with known triggers/situations where avoiding migraine is preferred. Rimegepant, indicated for acute and preventive migraine treatment, potentially provides patients with a flexible option for STP.

Design/Methods:
Perspectives of US HCPs who treated patients with migraine, prescribed migraine medications in the past 3 months, and aware of STP were collected through an online survey. A separate online survey collected perspectives of rimegepant STP users — US adults with migraine who used rimegepant for STP in the past 3 months, regardless if they also took rimegepant for long-term prevention and/or acute treatment.
Results:

Among 277 HCPs, 86% discussed STP with their patients with migraine. Over 90% of HCPs agreed that STP should be discussed with patients who have reliable triggers or specific situations when migraine avoidance is preferred. HCPs considered efficacy and side effects/tolerability as the most important treatment considerations when discussing STP with patients. HCPs mostly prescribed gepants for STP, with rimegepant as the preferred gepant. Among 152 STP users, 88% were informed about the use of rimegepant for STP by their prescriber physician and 61% received their first rimegepant prescription from a primary care provider. Patients had taken rimegepant for STP once (36%), daily (38%), or every other day (QOD, 42%). Patients last used rimegepant as STP for 1 (24%), 2-3 (52%), 4-10 (16%), or >10 (9%) days. Most patients were satisfied/extremely satisfied with rimegepant for STP after taking it once (80%), daily (77%), or QOD (77%).

Conclusions:

HCPs support discussing STP with patients who have predictable triggers/specific situations to prevent a migraine attack. Findings suggest that both HCPs and patients perceive the potential benefits of STP and flexible use of rimegepant for STP.

10.1212/WNL.0000000000212921
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.